Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model

AAPS PharmSci

Volumn 3, Issue 3, 2001, Pages

  Lee, Lai Ming ^a   Chang, Li Chien ^b   Wrobleski, Shirley ^c   Wakefield, Thomas W ^c   Yang, Victor C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anti lla anti xa; aPTT TCT heparin clotting; Assays; Chromogenic assays; Hemodynamic hematologic; Heparin neutralization; Protamine toxicity; Responses

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; BLOOD CLOTTING FACTOR 10A; DRUG TOXICITY; FACTOR IIA; HEPARIN; HEPARIN ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; LOW MOLECULAR WEIGHT PROTAMINE; PEPTIDE ANTIBODY; PEPTIDE FRAGMENT; PHARMACOLOGY; PROTAMINE; PROTAMINE SULFATE; PROTHROMBIN; PROTHROMBIN A; THERMOLYSIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD PRESSURE; BLOOD TOXICITY; CHEMISTRY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG SYNTHESIS; ENZYMATIC DEGRADATION; IN VIVO STUDY; LUNG WEDGE PRESSURE; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBIN TIME;

ANIMALS; ANTAGONISTS AND INHIBITORS; ANTICOAGULANTS; BLOOD CELL COUNT; BLOOD COAGULATION; BLOOD PRESSURE; CHEMISTRY; DOGS; DRUG EFFECTS; FACTOR XA; HEPARIN; HEPARIN ANTAGONISTS; MALE; PEPTIDE FRAGMENTS; PHARMACOLOGY; PROTAMINES; PROTHROMBIN; PROTHROMBIN TIME; PULMONARY WEDGE PRESSURE; TOXICITY;

EID: 0035783265     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Ando T, Yamasaki M, Suuzuki K. In: Kleinzeller A, ed. Protamine: Molecular Biology, Biochemistry and Biophysics. Vol 12. New York: Springer-Verlag; 1973:1-109.
2. Metz S, Horrow JC. Protamine and newer heparin antagonists. In: Stoelting RK, eds. Pharmacology and Physiology in Anesthetic Practice. Vol 1, No 3. Philadelphia, Pa: JB Lippincott; 1994:1-15.
3. Weiler JM, Gelhaus MA, Carter JG, et al. Serious adverse reactions to protamine sulfate: are alternatives needed? J Allergy Clin Immunol. 1985;75:297-303.
4. Horrow JC. Protamine: a review of its toxicity. Anesth Analg. 1985;64:348-361.
5. Porsche R, Brenner ZR. Allergy to protamine sulfate. Heart Lung: J Acute Crit Care. 1999;28:418-428.
6. Carr JA, Silverman N. The heparin-protamine interaction. J Cardiovasc Surg. 1999;40:659-666.
7. Click RL, Homburger HA, Bove AA. Complement activation from protamine sulfate administration after coronary angiography. Catheter Cardiovasc Diagn. 1989;16:221-225.
8. Conzen PF, Habazettl H, Gutmann R, et al. Thromboxane mediation of pulmonary hemodynamic responses after neutralization of heparin by protamine in pigs. Anesth Analg. 1989;68:25-31.
9. Rent R, Ertel N, Eisenstein R, Gewurz H. Complement activation by interaction of polyanions and polycations, I. Heparin-protamine induced consumption of complement. J Immunol. 1975;114:120-124.
10. Shanberge JN, Murato M, Quattrociocchi-Longe T, Neste LV. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures. Am J Clin Pathol. 1987;87:210-217.
11. Wakefield TW, Andrews PC, Wrobleski SK, et al. A [+18RGD] protamine-variant for nontoxic and effective reversal of heparin and low molecular weight heparin anticoagulation. J Surg Res. 1996;63:280-286.
12. DeLucia A, Wakefield TW, Andrews, PC, et al. Efficacy and toxicity of differently charged polycationic protamine-like peptides for heparin anticoagulation reversal. J Vasc Surg. 1993;18:49-60.
13. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 1972;9:248-257.
14. Gobel-Geard RJ, Hassouna HI. Interaction of protamine sulfate with thrombin. Am J Hematol. 1983;14:227-233.
15. Chang LC, Liang J, Lee HF, Lee LM, Yang VC. Low molecular weight protamine (LMWP) as a nontoxic heparin/low molecular weight heparin antidote. I: preparation and characterization. AAPS PharmSci. 2001; 3(2) Article 17; Available from: http://www.pharmsci.org/scientificjournals/pharmsci/journal/01.html
16. Chang LC, Lee LM, Liang J, Yang VC. Low molecular weight protamine (LMWP) as a nontoxic heparin/low molecular weight heparin antidote. II: in vitro evaluation of efficacy and toxicity. AAPS PharmSci. 2001; 3(2) Article 18; Available from: http://www.pharmsci.org/scientificjournals/pharmsci/journal/01.html
17. Yang VC, Port FK, Kim JS, Teng CL, Till GO, Wakefield TW. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation. Anesthesiology. 1991;75:288-297.
18. Jaques LB. Heparin-anionic polyelectrolyte drugs. Pharmacol Rev. 1979;33:99-166.
19. Conahan TJ, Andrews RW, MacVaugh H. Cardiovascular effects of protamine sulfate in man. Anesth Analg. 1981;60:33-36.
20. Ellison N, Beatty CP, Blake DR, Wurzel HA, MacVaugh H. Heparin rebound studies in patients and volunteers. J Thorac Cardiovas Surg. 1974;67:723-729.
21. Fabian I, Aronson M. Mechanism of heparin rebound: in vitro study. Thromb Res. 1980;18:535-542.
22. Morel DR, Mo Costabella PM, Pitter J. Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin and protamine in awake sheep are infusion rate-dependent. Anesthesiology. 1990;73:415-424.
23. Parkinson C, Grasso P. The use of the dog in toxicity tests on pharmaceutical compounds. Hum Experimental Toxicol. 1993;12:99-109.
24. Wakefield TW, Whitehouse WM Jr, Stanley JC. Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity. J Vasc Surg. 1986;1:346-355.
25. Jacob HS, Craddock PR, Hammersmidt DE, Moldow CF. Complement-induced granulocyte aggregation. N Engl J Med. 1980;302:789-794.
26. Cavarocchi N, Schaff HV, Homburge HA, Schnell WA. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass. Surgery. 1985;98:525-531.